Reach Us +44-1647-403003
Expression Of Ganglioside GD2, As A Novel Cancer Stem Cell Marker In Breast Carcinomas | 85350
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Share This Page

Expression of ganglioside GD2, as a novel cancer stem cell marker in breast carcinomas

7th World Congress on Breast Cancer

Mansoori M

Iran University of Medical Sciences, Iran

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C2-126

Introduction: Cancer stem cells (CSCs) are attractive for many researchers because of their diagnostic, prognostic and therapeutic implications. Here, we aim to investigate the local expression of ganglioside GD2, as the recently proposed breast CSC (BCSC) marker, through the assessment of GD2 synthase mRNA, the key enzyme involved in GD2 synthesis. Material & Methods: Fresh tumor tissues along with normal adjacent tissues from 65 patients who underwent surgery for breast cancer were collected. Total RNAs of tumoral and normal tissue samples were extracted and analyzed using real-time PCR. The mRNA expression pattern of GD2 was compared in tumoral and control tissue samples using ΔΔCT method. The relevance of GD2 synthase level with clinical characteristics of the patients was also evaluated. Results: The expression level of GD2 synthase was significantly higher in breast cancer tissue samples compared to normal adjacent tissues (4.92-fold change, p<0.001). GD2 synthase expression was also significantly higher in advanced grades tumor (2 and 3) (p=0.001) and in patients at stages III and IV compared to stages I and II (p=0.001). Whereas, the correlation between GD2 synthase and other clinicopathologic data was not statistically significant, such as for age (p=1.000), type of carcinoma (p=0.934), lymphatic invasion (p=0.139) and tumor size (p=0.066). Conclusion: The higher expression of GD2 synthase in tumoral tissue samples of breast cancer patients further potentiates it as a BCSC marker which could be used for clinical implications such as diagnosis, monitoring and prognosis of breast cancer

Mansoori M is pursuing her last semester of PhD in Iran University of Medical Sciences, Tehran Iran. She has ranked 5th in PhD entrance exam among 500 candidates. She has published four papers in reputed journals.
Email:[email protected]

Relevant Topics